Galderma Presents P-III Trial (OLYMPIA 2) of Nemolizumab for Prurigo Nodularis at AAD 2023
Shots:
- The P-III trial evaluating nemolizumab vs PBO in 274 patients aged 18yrs. The trial met all 1EPs i.e., improvement in pruritus (itch) & skin lesions, 56% vs 21% achieved a response in itch intensity as defined by 4-point improvement in PP-NRS score, 38% vs 11% reached treatment success in skin lesions as defined by IGA score of 0 or 1
- The 2EPs showed rapid onset of action & improvements in itch & sleep disturbance as early as 4wk., clinical improvement in itch intensity as defined by a 4-point improvement in PP-NRS (41.0% vs 7.7%) & sleep disturbance as measured by a 4-point improvement in SD-NRS (37.2% vs 9.9%)
- The safety profile was consistent with the P-II trial results. Nemolizumab received BTD from the US FDA for pruritus associated with PN in Dec 2019
Ref: Businesswire | Image: Galderma
Related News:- Galderma Reports Results of Nemolizumab in P-III (OLYMPIA 2) Trial for the Treatment of Prurigo Nodularis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
